TABLE 1.
Baseline characteristics of 157 patients in the bendamustine and rituximab (BR) cohort
| Variable (n. of patients) | N. of patients (%) |
|---|---|
| age ≤ 65/>65 years (n = 157) | 30 (19.1)/127 (80.9) |
| median age (range) (n = 157) | 72.5 (39‐89) |
| stage a early/intermediate‐advanced (n = 129) | 53 (41.1)/76 (58.9) |
| gender male/female (n = 157) | 95 (60.5)/62 (39.5) |
| ECOG PS 0/1/ ≥2 (n = 154) | 68 (43.3)/70 (44.6)/ 16 (10.2) |
| N. of comorbidities 0‐1/≥ 2 (n = 156) | 48 (30.8)/108 (69.2) |
| Median Cr Cl ml/min (range) (n = 157) | 59.8 (22.0−137.0) |
| beta 2 microglobulin ≥ 3.5/<3.5 mg/L (n = 113) | 94 (83.2)/19 (16.8) |
| IGHV Mutated/Unmutated (n = 89) | 44 (49.4)/45 (50.6) |
| 17p‐ and/or TP53 mutated yes/no (n = 131) | 23 (17.6)/108 (82.4) |
| FISH abns 13q‐/+12/11q‐/17p‐/normal (n = 111) | 34 (30.6)/24 (21.6)/10 (9.0)/7 (6.3)/36 (32.4) |
Legend: ECOG PS, Eastern Cooperative Oncology Group Performance Status; Cr Cl, Creatinine clearance.
a
Early: Binet A.